I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

Presentation of Cantargia’s report for the third quarter of 2021

November 11th at 3.00 PM CET

CEO Interview

To the interview (In Swedish)

CEO presentation AGM

To the presentation (In Swedish)

CEO interview

To the interview (in Swedish)

Cantargia in a panel discussion on how to build a successful biotech company

Panel discussion (in Swedish)

Press releases

2021-11-11 (R) Cantargia publishes interim report for third quarter 2021

2021-11-08 (R) Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10

2021-11-08 Invitation to presentation of Cantargia’s report for the third quarter of 2021 on November 11 at 3.00 p.m. CET

(R) = Regulatory press releases

”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Göran Forsberg

CEO Cantargia

Analysis

2021-11-25, Aktiespararna analysis of Cantargia (In Swedish)

2021-11-12, Nordea analys av Cantargia

2021-09-27, Aktiespararna analysis of Cantargia (In Swedish)

2021-05-27, Nordea analysis of Cantargia

Presentations

2021-09-28, Video, Aktiespararna, Aktiedagen, Lund (In Swedish)

2021-09-28, Presentation, Aktiespararna, Aktiedagen, Lund

2021-09-22, Video, ØU Life Science Investor conference 2021

2021-09-22, Presentation, ØU Life Science Investor Konference 2021

© Copyright 2021 · Cantargia AB